Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals

Khan, Tauseef A., Shah, Tina, Prieto, David, Zhang, Weili, Price, Jackie, Fowkes, Gerald R., Cooper, Jackie, Talmud, Philippa J., Humphries, Steve E., Sundstrom, Johan, Hubacek, Jaroslav A., Ebrahim, Shah, Lawlor, Debbie A., Ben-Shlomo, Yoav, Abdollahi, Mohammad R., Slooter, Arjen J.C., Szolnoki, Zoltan, Sandhu, Manjinder, Wareham, Nicholas, Frikke-Schmidt, Ruth, Tybjærg-Hansen, Anne, Fillenbaum, Gerda, Heijmans, Bastiaan T., Katsuya, Tomohiro, Gromadzka, Grazyna, Singleton, Andrew, Ferrucci, Luigi, Hardy, John, Worrall, Bradford, Rich, Stephen S, Matarin, Mar, Whittaker, John, Gaunt, Tom R., Whincup, Peter, Morris, Richard, Deanfield, John, Donald, Ann, Davey Smith, George, Kivimaki, Mika, Kumari, Meena, Smeeth, Liam, Khaw, Kay-Tee, Nalls, Michael, Meschia, James, Sun, Kai, Hui, Rutai, Day, Ian, Hingorani, Aroon D. and Casas, Juan P. (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. International Journal of Epidemiology, 42 (2), 475-492. (doi:10.1093/ije/dyt034). (PMID:23569189)

Abstract

Background: at the APOE gene, encoding apolipoprotein E, genotypes of the ?2/?3/?4 alleles associated with higher LDL-cholesterol (LDL-C) levels are also associated with higher coronary risk. However, the association of APOE genotype with other cardiovascular biomarkers and risk of ischaemic stroke is less clear. We evaluated the association of APOE genotype with risk of ischaemic stroke and assessed whether the observed effect was consistent with the effects of APOE genotype on LDL-C or other lipids and biomarkers of cardiovascular risk.

Methods: we conducted a systematic review of published and unpublished studies reporting on APOE genotype and ischaemic stroke. We pooled 41 studies (with a total of 9027 cases and 61 730 controls) using a Bayesian meta-analysis to calculate the odds ratios (ORs) for ischaemic stroke with APOE genotype. To better evaluate potential mechanisms for any observed effect, we also conducted a pooled analysis of primary data using 16 studies (up to 60 883 individuals) of European ancestry. We evaluated the association of APOE genotype with lipids, other circulating biomarkers of cardiovascular risk and carotid intima-media thickness (C-IMT).

Results: the ORs for association of APOE genotypes with ischaemic stroke were: 1.09 (95% credible intervals (CrI): 0.84–1.43) for ?2/?2; 0.85 (95% CrI: 0.78–0.92) for ?2/?3; 1.05 (95% CrI: 0.89–1.24) for ?2/?4; 1.05 (95% CrI: 0.99–1.12) for ?3/?4; and 1.12 (95% CrI: 0.94–1.33) for ?4/?4 using the ?3/?3 genotype as the reference group. A regression analysis that investigated the effect of LDL-C (using APOE as the instrument) on ischaemic stroke showed a positive dose-response association with an OR of 1.33 (95% CrI: 1.17, 1.52) per 1 mmol/l increase in LDL-C. In the separate pooled analysis, APOE genotype was linearly and positively associated with levels of LDL-C (P-trend: 2 × 10?152), apolipoprotein B (P-trend: 8.7 × 10?06) and C-IMT (P-trend: 0.001), and negatively and linearly associated with apolipoprotein E (P-trend: 6 × 10?26) and HDL-C (P-trend: 1.6 × 10?12). Associations with lipoprotein(a), C-reactive protein and triglycerides were non-linear.

Conclusions: in people of European ancestry, APOE genotype showed a positive dose-response association with LDL-C, C-IMT and ischaemic stroke. However, the association of APOE ?2/?2 genotype with ischaemic stroke requires further investigation. This cross-domain concordance supports a causal role of LDL-C on ischaemic stroke

This record has no associated files available for download.

Contributors

Download statistics